SCHEMBL167257

SCHEMBL167257

CCOC(=O)C(OC)C(=O)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 2/20 0.34
LMNA P02545 1/20 0.34
HDAC4 P56524 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
GAA P10253 2/20 0.33
ALOX15 P16050 2/20 0.33
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
SOAT1 P35610 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
MMP8 P22894 1/20 0.33
KMT2A Q03164 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20848427 0.84 ALDH1A1 (0.36) ALDH1A1HSD17B10LMNAHDAC4HDAC6
SCHEMBL1562108 0.80 ALDH1A1 (0.48) ALDH1A1HSD17B10LMNAGAAALOX15
SCHEMBL9068703 0.77 ALDH1A1 (0.40) ALDH1A1HSD17B10LMNAHDAC4HDAC6
SCHEMBL1770642 0.75 ALDH1A1 (0.39) ALDH1A1HSD17B10LMNAHDAC4HDAC6
SCHEMBL196658 0.75 ALDH1A1 (0.39) ALDH1A1HSD17B10LMNAHDAC4HDAC6
SCHEMBL23473944 0.75 ALDH1A1 (0.39) ALDH1A1HSD17B10LMNAHDAC4HDAC6
SCHEMBL13718845 0.74 MGAM (0.44) ALDH1A1HSD17B10LMNAGAAALOX15
SCHEMBL4755149 0.74 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAGAAALOX15
SCHEMBL1333841 0.74 ALDH1A1 (0.46) ALDH1A1HSD17B10LMNAGAAALOX15
SCHEMBL290478 0.73 ALDH1A1 (0.37) ALDH1A1HSD17B10LMNAHDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695239-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-02-18 EP disclosed
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition CENTENNIAL THERAPEUTICS, LLC 2024-12-12 US disclosed
WO-2024216034-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-10-17 WO disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
EP-2611808-B1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-12 EP disclosed
EP-2611808-B1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-12 EP disclosed
US-8859775-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2014-10-14 US disclosed
US-8859775-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2014-10-14 US disclosed
US-8859775-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2014-10-14 US disclosed
EP-2611808-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS Merck Patent GmbH (DE) 2013-07-10 EP disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
WO-2012028243-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2012-03-08 WO disclosed
WO-2012028243-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 ALDH1A1 985/4885HSD17B10 1429/4885LMNA 1353/4885
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition KHK, GCK, HK1 ALDH1A1 1031/4885HSD17B10 805/4885LMNA 4402/4885
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 ALDH1A1 985/4885HSD17B10 1429/4885LMNA 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.